Work

Abstract CT045: A phase 1/2 trial of TAC-001 (TLR9 agonist-CD22 mAb) in advanced or metastatic solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct045

Authors: Jason T. Henry, Anna C. Pavlick, Timothy Humphries, Sunnie Kim, Martin Gutierrez, Sarina A. Piha-Paul, Daniel Vaena, Shiraj Sen, Alexander Spira, Guru Sonpavde, Ons Harrabi, Feng Jin, Sangeetha Bollin, Laura QM Chow, Hong I. Wan, Cesar A. Perez

Institutions: HealthONE, Weill Cornell Medicine, University of Colorado Anschutz, Hackensack University Medical Center, The University of Texas MD Anderson Cancer Center, West Cancer Center, AdventHealth Orlando

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822322

Cites:

Cited by: 5

Related to: 10